This content is only available within our institutional offering.
20 Sep 2017
LIBERUM: Shield Therapeutics* - No material changes to our in-market sales expectations, US P3 now due early 2018, IDA label filed early
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Shield Therapeutics* - No material changes to our in-market sales expectations, US P3 now due early 2018, IDA label filed early
Shield Therapeutics Plc (STX:LON) | 10.1 0 0.0% | Mkt Cap: 107.9m
- Published:
20 Sep 2017 -
Author:
Roger Franklin | Graham Doyle -
Pages:
4 -